CN105408480A - 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法 - Google Patents

用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法 Download PDF

Info

Publication number
CN105408480A
CN105408480A CN201480026966.0A CN201480026966A CN105408480A CN 105408480 A CN105408480 A CN 105408480A CN 201480026966 A CN201480026966 A CN 201480026966A CN 105408480 A CN105408480 A CN 105408480A
Authority
CN
China
Prior art keywords
polynucleotide
ogt
composition
seqidno
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026966.0A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·鲁本斯坦
卡斯培·鲁纳杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN105408480A publication Critical patent/CN105408480A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01186—Glycogenin glucosyltransferase (2.4.1.186)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01255—Protein O-GlcNAc transferase (2.4.1.255)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Power Engineering (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
CN201480026966.0A 2013-03-11 2014-03-11 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法 Pending CN105408480A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775937P 2013-03-11 2013-03-11
US61/775,937 2013-03-11
PCT/US2014/023525 WO2014164805A1 (en) 2013-03-11 2014-03-11 Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing

Publications (1)

Publication Number Publication Date
CN105408480A true CN105408480A (zh) 2016-03-16

Family

ID=51658978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026966.0A Pending CN105408480A (zh) 2013-03-11 2014-03-11 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法

Country Status (13)

Country Link
US (1) US20170166897A1 (https=)
EP (1) EP2970978A4 (https=)
JP (1) JP2016513968A (https=)
KR (1) KR20150126048A (https=)
CN (1) CN105408480A (https=)
AU (1) AU2014248966A1 (https=)
BR (1) BR112015022701A2 (https=)
CA (1) CA2905337A1 (https=)
CL (1) CL2015002599A1 (https=)
MX (1) MX2015012124A (https=)
RU (1) RU2015138544A (https=)
SG (1) SG11201507211YA (https=)
WO (1) WO2014164805A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111234022A (zh) * 2019-12-16 2020-06-05 南京泰斯德生物科技有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
CN112707955A (zh) * 2020-12-21 2021-04-27 山东润德生物科技有限公司 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146883B2 (en) * 2018-12-06 2024-11-19 Biocapital Holdings, Llc Glucose sensors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044123A2 (en) * 1997-03-31 1998-10-08 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services O-LINKED GlcNAc TRANSFERASE (OGT): CLONING, MOLECULAR EXPRESSION, AND METHODS OF USE
CN101356437A (zh) * 2005-12-22 2009-01-28 J-油坊株式会社 具有由GnT-V转移的GlcNAc的糖链的检测方法
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
EP1102786A4 (en) * 1998-08-03 2002-03-06 Univ East Carolina AGENT COMPRISING ANTISENSE OLIGONUCLEOTIDES WITH LOW ADENOSINE CONTENT, COMPOSITION, KIT AND TREATMENTS
EP2314321B1 (en) * 1999-01-27 2014-06-04 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
JP2012083193A (ja) * 2010-10-12 2012-04-26 Univ Of Tokyo ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044123A2 (en) * 1997-03-31 1998-10-08 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services O-LINKED GlcNAc TRANSFERASE (OGT): CLONING, MOLECULAR EXPRESSION, AND METHODS OF USE
CN101356437A (zh) * 2005-12-22 2009-01-28 J-油坊株式会社 具有由GnT-V转移的GlcNAc的糖链的检测方法
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111234022A (zh) * 2019-12-16 2020-06-05 南京泰斯德生物科技有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
CN111234022B (zh) * 2019-12-16 2024-03-22 江苏省药物研究所有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
CN112707955A (zh) * 2020-12-21 2021-04-27 山东润德生物科技有限公司 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体
CN112707955B (zh) * 2020-12-21 2022-01-18 山东润德生物科技有限公司 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体

Also Published As

Publication number Publication date
CL2015002599A1 (es) 2016-08-26
KR20150126048A (ko) 2015-11-10
JP2016513968A (ja) 2016-05-19
SG11201507211YA (en) 2015-10-29
AU2014248966A1 (en) 2015-10-29
BR112015022701A2 (pt) 2018-09-25
US20170166897A1 (en) 2017-06-15
EP2970978A4 (en) 2016-11-02
CA2905337A1 (en) 2014-10-09
RU2015138544A (ru) 2017-04-18
MX2015012124A (es) 2016-04-28
EP2970978A1 (en) 2016-01-20
WO2014164805A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
JP6768701B2 (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
Wang et al. Inositol-requiring enzyme 1 facilitates diabetic wound healing through modulating microRNAs
US20100279921A1 (en) Impaired wound healing compositions and treatments
US20240035026A9 (en) Hnf4a sarna compositions and methods of use
KR20100027091A (ko) 상처 치유를 위한 개선 방법 및 조성물
JP2017148075A (ja) 創傷治癒組成物および治療
JP7132646B2 (ja) ケロイドまたは肥厚性瘢痕の予防または治療用組成物
KR20090118910A (ko) 치유 부전 상처를 치유하는 조성물로서의 항-커넥신 폴리뉴클레오티드
JP2012500199A (ja) 血管統合性を促進するマイクロ−ｒｎａおよびその使用
CN106062194A (zh) 用于调整肌腱愈合的材料和方法
Smid et al. Periostin induces pancreatic regeneration
Fang et al. Improvement of skin wound healing for diabetic mice with thermosensitive hydrogel combined with insulin injection
JP6238319B2 (ja) 創傷または線維症の治療剤
CN105408480A (zh) 用于靶向o-连接的n-乙酰氨基葡萄糖转移酶和促进伤口愈合的组合物和方法
JP2015513905A (ja) カドヘリン調節に基づく組成物および処置
WO2019080284A1 (zh) 一种药物作用靶点的组合物和应用
US20160244759A1 (en) Compositions and treatments based on cadherin modulation
JP6363737B2 (ja) 瘢痕形成を軽減する医薬組成物及び方法
WO2016149187A1 (en) Methods to accelerate wound healing in diabetic subjects
CN121852383A (zh) 靶向肝Sam68的双链siRNA及其在代谢综合征相关疾病中的用途
US20170152296A1 (en) Compositions for the treatment of wounds
Zhou Persistent Choroidal Thinning Associated with Retinopathy of Prematurity: A Tale of Two Molecules–IL-1β and p53
CA2941140A1 (en) Treatment of resistant lesions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160316

WD01 Invention patent application deemed withdrawn after publication